Explore the words cloud of the ScleroTest project. It provides you a very rough idea of what is the project "ScleroTest" about.
The following table provides information about the project.
|Coordinator Country||Spain [ES]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-06-01 to 2019-11-30|
Take a look of project's partnership.
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system currently affecting about 2.5 million people worldwide (mainly young adults, three times more women than men). There is no cure and therapies do not properly work in all patients. Personalized medicine is needed but we lack predictive biomarkers for treatment response to secure prompt and early treatment and the best clinical outcomes for each patient. Thus, MS represents a major public health issue with a substantial socioeconomic impact (€15.5 B annual costs in Europe). Bioithas is a biotechnology company in the field of health developing new diagnostic and therapeutic targets for autoimmune and inflammatory diseases. In response to the unmet need, it is focused on developing the first-ever gut microbiota based biomarker for predicting MS treatment response. ScleroTest, a quick point-of-care (PoC) diagnostic tool, will allow immunomodulatory profiling of patients to predict treatment response. It is a non-invasive, accurate (PCR performance), rapid (results in <24 h) and cost-competitive test (€25 test, ca. 58 % cheaper than magnetic resonance and JC virus alternatives). ScleroTest implantation in routine practice will face current MS management problems resulting on added value for patients, neurologists and health systems by allowing fast and correct therapy choice, better clinical outcomes and cost-savings. ScleroTest scalability will also open new avenues for personalized therapy in other diseases. Due to ScleroTest´s cost-competitive features plus the absence of real competition, the increasing MS prevalence and incidence globally and the growing PoC market (CAGR 10%, €33 B by 2022), Bioithas foresees ScleroTest as a fruitful business opportunity (accumulated net profit ca. €18.02 M, 2022-2026). To secure the successful market launch, we will perform a feasibility study analyzing technological, commercial and financial aspects to finalize our business plan.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCLEROTEST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SCLEROTEST" are provided by the European Opendata Portal: CORDIS opendata.